Galmed Pharmaceuticals Ltd. (GLMD)

Market Cap	3.06M
Revenue (ttm)	n/a
Net Income (ttm)	-7.52M
Shares Out	2.26M
EPS (ttm)	-8.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,703
Open	1.388
Previous Close	1.380
Day's Range	1.352 - 1.355
52-Week Range	1.210 - 23.800
Beta	0.70
Analysts	Hold
Price Target	n/a
Earnings Date	May 29, 2025

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 13, 2014
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: GLMD
• Website: https://www.galmedpharma.com